Metabolic dysfunction-associated steatohepatitis (MASH) is an advanced form of metabolic dysfunction-associated steatotic liver disease (MASLD). MASLD occurs when fat builds up in the liver, causing ...

Company remains on track to resubmit new drug application (NDA) for OCA in its lead indication of fibrosis due to NASH by year end based on its positive Phase 3 REGENERATE study MORRISTOWN, N.J., Sept ...

Advanced liver cirrhosis can push levels of ammonia in the blood to hazardous levels, but skipping meat at mealtime can help reverse that, new research shows. "It was exciting to see that even small ...

Among patients with baseline and week 96 biopsies, 39% of the 50mg EFX group (p=0.009) demonstrated ≥1 stage improvement in fibrosis with no worsening of MASH, representing a 24% effect size over ...

Akero's 50mg EFX led to a 24% effect size for cirrhosis reversal over placebo in week 96 biopsies, highlighting treatment potential. Non-GLP-1 subgroup saw 45% cirrhosis reversal with EFX, showing ...

Phase 2b SYMMETRY study preliminary results showed statistically significant reversal of compensated cirrhosis (F4) due to MASH following 96 weeks of treatment with efruxifermin (EFX) Presented two ...

Metabolic-associated steatohepatitis (MASH) happens when excess fat in the liver causes inflammation and scarring, or fibrosis. The condition is serious, and when left untreated it can lead to ...

Semaglutide reduced liver fibrosis and resolved MASH in the ESSENCE trial, offering dual hepatic and metabolic benefits. Read more.

For decades, the search for effective treatments for metabolic dysfunction-associated steatohepatitis (MASH) — a form of fatty liver disease — has been marked by disappointment. Despite the growing ...

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...

SOUTH SAN FRANCISCO, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious ...